Published in Int J Cancer on November 01, 2004
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol (2009) 2.25
Promising molecular targets and biomarkers for male BPH and LUTS. Curr Urol Rep (2013) 1.43
Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate (2009) 1.37
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res (2009) 1.20
CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One (2012) 1.03
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol (2007) 1.03
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol (2007) 0.97
Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth. Integr Biol (Camb) (2012) 0.97
Stromal expression of decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer. PLoS One (2012) 0.92
Role of tumor associated fibroblasts in human liver regeneration, cirrhosis, and cancer. Int J Hepatol (2011) 0.86
MicroRNA regulation in cancer-associated fibroblasts. Cancer Immunol Immunother (2011) 0.84
Gene targeting to the stroma of the prostate and bone. Differentiation (2008) 0.84
Differences in the nemosis response of normal and cancer-associated fibroblasts from patients with oral squamous cell carcinoma. PLoS One (2009) 0.81
Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression. Cancer Lett (2016) 0.75
Matrix metalloproteinases activity and stromal-epithelial interactions. Int J Cancer (2005) 0.75
Spaced education improves the retention of clinical knowledge by medical students: a randomised controlled trial. Med Educ (2007) 2.40
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol (2012) 1.86
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate (2006) 1.76
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol (2005) 1.63
Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol (2007) 1.62
Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int (2014) 1.58
Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J Urol (2012) 1.58
Management of spermatic cord tumors: a rare urologic malignancy. Ther Adv Urol (2012) 1.56
MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics (2008) 1.54
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res (2013) 1.49
Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol (2006) 1.48
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell (2007) 1.47
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract (2014) 1.47
Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol (2003) 1.45
Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res (2002) 1.43
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol (2006) 1.38
Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate (2009) 1.37
Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology (2003) 1.35
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A (2007) 1.30
Human embryonal carcinoma tumor antigen, Gp200/GCTM-2, is podocalyxin. Biochem Biophys Res Commun (2003) 1.29
Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res (2004) 1.28
Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res (2006) 1.28
Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol (2004) 1.28
Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology (2006) 1.27
Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res (2005) 1.27
Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem (2003) 1.25
MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res (2007) 1.20
Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene (2004) 1.20
Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis (2006) 1.17
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate (2004) 1.17
Tissue slice grafts: an in vivo model of human prostate androgen signaling. Am J Pathol (2010) 1.16
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate (2013) 1.15
Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer (2003) 1.15
The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells (2006) 1.15
MR classification of renal masses with pathologic correlation. Eur Radiol (2007) 1.14
The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J Urol (2003) 1.10
c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res (2007) 1.09
Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A (2012) 1.09
Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol (2005) 1.05
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett (2006) 1.05
Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res (2012) 1.04
Comparing costs of robotic, laparoscopic, and open partial nephrectomy. J Endourol (2013) 1.03
CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res (2004) 1.03
Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues. J Cell Physiol (2007) 1.03
Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation (2008) 1.03
The role of vitamin D in prostate cancer. Recent Results Cancer Res (2003) 1.02
Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol (2007) 1.02
Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev (2003) 1.01
Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother Radiopharm (2010) 1.01
Association between prostate cancer and serum testosterone levels. Prostate (2002) 0.99
Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol (2007) 0.97
Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol (2012) 0.97
Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res (2009) 0.97
Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med (2005) 0.97
Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res (2008) 0.96
Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate (2011) 0.96
Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw (2013) 0.95
P53 and Fas are sequential mechanisms of testicular germ cell apoptosis. J Androl (2002) 0.94
Smaller prostate gland size and older age predict Gleason score upgrading. Urol Oncol (2011) 0.94
Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate (2003) 0.94
Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J Bone Miner Res (2007) 0.94
Retinol metabolism and lecithin:retinol acyltransferase levels are reduced in cultured human prostate cancer cells and tissue specimens. Cancer Res (2002) 0.93
A multi-institutional randomized controlled trial of adjuvant Web-based teaching to medical students. Acad Med (2006) 0.93
Cadmium-induced neoplastic transformation of human prostate epithelial cells. Int J Oncol (2002) 0.93
A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology (2002) 0.92
Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Urology (2011) 0.92
Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol (2003) 0.91
Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J Nutr (2007) 0.91
Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. Bioorg Med Chem Lett (2011) 0.90
Methods for metabolic evaluation of prostate cancer cells using proton and (13)C HR-MAS spectroscopy and [3-(13)C] pyruvate as a metabolic substrate. Magn Reson Med (2009) 0.90
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics (2009) 0.90
Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol (2003) 0.89
Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer (2009) 0.89
Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res (2006) 0.89
Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer (2009) 0.89
Targeting monoamine oxidase A in advanced prostate cancer. J Cancer Res Clin Oncol (2010) 0.88
Inhibition of TNF-α improves the bladder dysfunction that is associated with type 2 diabetes. Diabetes (2012) 0.88
Development of a sensitive and specific enzyme-linked immunosorbent assay for thymosin beta15, a urinary biomarker of human prostate cancer. Clin Biochem (2005) 0.86
Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells. J Cell Physiol (2002) 0.86
The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin. PLoS One (2011) 0.86
Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. Cancer Lett (2005) 0.86
Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol (2007) 0.86
Induced pluripotency of human prostatic epithelial cells. PLoS One (2013) 0.86
Integrated analysis reveals critical genomic regions in prostate tumor microenvironment associated with clinicopathologic phenotypes. Clin Cancer Res (2012) 0.86
A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urol (2012) 0.86
Determinations of prostate volume at 3-Tesla using an external phased array coil: comparison to pathologic specimens. Acad Radiol (2003) 0.85
Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin Cancer Res (2007) 0.85
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts. Int J Cancer (2013) 0.85
Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate (2013) 0.84